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Abstract
In Alzheimer’s disease (AD) a variety of amyloid β-peptides (Aβ) are deposited in the form of extracellular diffuse
and neuritic plaques (NP), as well as within the vasculature. The generation of Aβ from its precursor, the amyloid
precursor protein (APP), is a highly complex procedure that involves subsequent proteolysis of APP by β- and γ-
secretases. Brain accumulation of Aβ due to impaired Aβ degradation and/or altered ratios between the different
Aβ species produced is believed to play a pivotal role in AD pathogenesis. While the presence of Aβ40 and Aβ42 in
vascular and parenchymal amyloid have been subject of extensive studies, the deposition of carboxyterminal
truncated Aβ peptides in AD has not received comparable attention. In the current study, we for the first time
demonstrate the immunohistochemical localization of Aβ37 and Aβ39 in human sporadic AD (SAD). Our study
further included the analysis of familial AD (FAD) cases carrying the APP mutations KM670/671NL, E693G and I716F,
as well as a case of the PSEN1 ΔExon9 mutation. Aβ37 and Aβ39 were found to be widely distributed within the
vasculature in the brains of the majority of studied SAD and FAD cases, the latter also presenting considerable
amounts of Aβ37 containing NPs. In addition, both peptides were found to be present in extracellular plaques but
only scarce within the vasculature in brains of a variety of transgenic AD mouse models. Taken together, our study
indicates the importance of C-terminally truncated Aβ in sporadic and familial AD and raises questions about how
these species are generated and regulated.
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Introduction
Amyloid-β (Aβ) peptides have been at the center of
Alzheimer’s disease (AD) research since their identifica-
tion as the main component of extracellular plaques
within the brains of AD patients [13, 28]. The amyloid
hypothesis states that an imbalance in the production
and clearance of Aβ initiates a cascade of pathological
events, including the hyperphosphorylation of tau, that
ultimately results in neuron loss [17]. Aβ peptides were
found to bear different characteristics depending on
their C-terminus, with Aβ42 proven to be extraordinar-
ily prone to aggregation [22]. At present, there is grow-
ing evidence that even subtle changes in the spectrum of
Aβ peptides, i.e. an increase of the ratio of Aβ42/40,
may facilitate AD pathogenesis, presumably through the
formation of toxic Aβ oligomers [16, 25].
Providing strong support for the amyloid cascade hy-
pothesis, rare point mutations within the amyloid pre-
cursor protein (APP) and presenilin (PSEN) genes have
been found to cause autosomal-dominant inheritance in
FAD [50]. Mechanisms by which FAD related mutations
can cause the disease include (i) an increased overall Aβ
production, (ii) a change in aggregation behavior of Aβ and
(iii) a shift in the Aβ peptide spectrum produced [4, 15].
Conclusions drawn from the study of these mechanisms
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may eventually translate into successful treatment of the
by far more common sporadic form of AD (SAD).
Aβ peptides are generated by sequential processing of
the single-transmembrane APP. In this process, the γ-
secretase, consisting of a complex containing PSEN
among other components, has been found to determine
the C-terminus of the peptide [3]. Its action is preceded
by β-secretase cleavage, releasing the soluble N-terminal
ectodomain (sAPPβ) and leaving a short membrane-
bound APP C-terminal fragment (β-CTF, C99) [35].
Current models describe the underlying mechanism by
which γ-secretase generates Aβ of varying length as a
stepwise cleavage of β-CTF APP, in which the initial ε-
cleavage critically affects the outcome [9] with cleavage
at either T48 or L49, resulting in subsequent production
of Aβ42 or Aβ40, respectively [6]. It has been proposed
that the products of ε-cleavage – Aβ49 and Aβ48 – are
further processed by subsequent γ-secretase cleavages at
every 3 to 4 residues, so that two major product lines
emerge: Aβ49 > Aβ46 > Aβ43 > Aβ40 and Aβ48 > Aβ45 >
Aβ42 > Aβ38. This hypothesis is based on the in vitro
detection of corresponding tri- and tetrapetides [43]. Re-
markably, several deviations from this scheme, like the
independent generation of Aβ38 from Aβ42, have been
reported [8, 39]. A recent study by Matsumura et al.
suggests a more complicated picture in which γ-
secretase action occasionally cleaves at every fourth, fifth
or even sixth residue, thereby interlinking the two major
product lines [29]. In addition, the production of further
Aβ species including Aβ37 and Aβ39 was demonstrated:
The release of the tripeptides GVV and VIA corresponds to
the generation of Aβ37 from Aβ40 and of Aβ39 from Aβ42
respectively. Furthermore, Aβ37 can also originate directly
from Aβ42, by release of the GVVIA pentapeptide [29].
So called γ-secretase modulators (GSMs) present a
pharmaceutical approach to change the Aβ spectrum
produced by γ-secretase, while not affecting other
physiological functions of the enzyme complex [12].
GSMs of the non-steroidal anti-inflammatory drug-type
have been shown to specifically decrease levels of Aβ42
in vitro, partially by shifting the production to C-
terminally truncated Aβ [3, 54]. Very recently, peptide
inhibitors based on the hexapeptide fragment Aβ32-37
have been generated. These inhibitors showed significant
Aβ aggregation inhibitory activity and mitigation of Aβ
toxicity, underscoring the importance of Aβ C-terminal
truncations [2].
While a plethora of studies have focused on the depos-
ition of the most abundantly produced species Aβ40 and
the presumably most toxic species Aβ42, the C-
terminally truncated species Aβ37, Aβ38 and Aβ39 have
received less attention. All three species have been re-
ported to be present in cerebrospinal fluid (CSF) [40, 55]
and human plasma [27] and might be of importance to
increase diagnostic accuracy when using CSF samples
[47], but immunohistochemical analysis for C-terminally
truncated Aβ species have so far only focused on Aβ38.
For this species, Moro et al. and our group recently re-
ported abundant deposition in the vasculature in spor-
adic AD (SAD) cases presenting severe cerebral amyloid
angiopathy (CAA), as well as within NP and vascular
amyloid deposits of different FAD cases [32, 44]. Our
present study extends these findings by the analyses of
the deposition of Aβ37 and Aβ39 in SAD, FAD and
common animal models of the disease. Very much like
Aβ38, we found both Aβ37 and Aβ39 to be detectable
within the vasculature of the majority of SAD cases in-
vestigated. In addition, we show the presence among
four FAD cases carrying either APP or PSEN1 muta-
tions. This includes the analysis of a recently described
novel APP mutation I716F [14]. Moreover, we found the
C-terminally truncated Aβ species to be deposited as
plaques within a variety of established transgenic mouse




We examined the brains of sporadic AD cases (n = 13;
age: 88.5 ± 4.2 years), AD with CAA (n = 2), Down syn-
drome (DS, n = 3) and several different familial AD cases
(n = 4) in comparison to non-demented control patients
(NDC) (n = 8; age: 80.5 ± 7.2 years). The mutations
underlying FAD were the APP mutations KM670/671NL
(Swedish), E693G (Arctic) [23], I716F [46] and the PSEN1
mutation ΔExon 9 [53]. Human brain samples were ob-
tained from the following sources: Netherlands Brain
Bank, University Hospital Helsinki, Medical University
Vienna and Uppsala University. Definite diagnoses were
based on established criteria and written informed consent
had been received from all subjects or their close relatives,
according to ethical regulations in each country.
Animal models of AD
Formalin-fixed and paraffin embedded brain tissue was
obtained from six transgenic mouse lines that are com-
monly used as AD models, namely PDAPP [10], APP23
[48], 3xTg [37], APP/PS1ΔEx9 [11], 5xFAD [36] and
APP/PS1KI [5] (Table 3).
Immunohistochemistry
Immunohistochemistry was performed on 4 μm sagittal
paraffin sections, as previously described [57]. In brief,
sections were deparaffinized in xylene and rehydrated
using an ascending series of ethanol (70 %, 95 %, and
100 %). Endogenous peroxidases were blocked by incu-
bation in 0.3 % H2O2 in 0.01 M PBS. Antigen retrieval
was achieved by boiling in 0.01 M citrate puffer and
Reinert et al. Acta Neuropathologica Communications  (2016) 4:24 Page 2 of 12
3 min incubation in 88 % formic acid (FA). Prior to in-
cubation with primary antibodies, blockage of non-
specific binding sites was secured by treatment with 4 %
skim milk and 10 % fetal calf serum in 0.01 M PBS for
1 h at ambient temperature. Mouse monoclonal anti-
bodies 4G8 (Covance, Dedham) against Aβ, G2-10
(Milipore, Schwalbach) against Aβ40, 326 F1 against
Aβ38 (#218421, Synaptic Systems, Göttingen), rabbit
monoclonal antibodies mAb12467 against Aβ37 and
mAb12077 against Aβ39 (both Cell Signaling) and a
rabbit polyclonal antibody against Aβ42 (#218703, Syn-
aptic Systems, Göttingen) were incubated overnight at
ambient temperature. Incubation with biotinylated sec-
ondary antibodies (DAKO, Glostrup, 1:200) was carried
out at 37 °C and was followed by applying the ABC
method with a Vectastain kit (Vector Laboratories,
Burlingame, USA) and diaminobenzidine as a chromo-
gen to reveal the staining. Hematoxylin was used for
counterstaining. Double-immunofluorescence staining
was performed using DyLight488 and DyLight594 fluor-
escent secondary antibodies (Thermofisher Scientific).
Counterstaining was performed with 4’6-diamidine-
2’phenylindole dihydrochloride (DAPI, Sigma-Aldrich,
Taufkirchen).
Mass spectrometry
Formic acid extraction of proteins from mouse brain
Three left brain hemispheres from 7-month-old female
5XFAD mice were homogenized to powder in liquid ni-
trogen. Aliquots of ~50 μg brain powder were re-
suspended in 300 μl PBS pH 7.4 supplemented with
cømplete protease-inhibitor (Roche, 1 tablet/10 ml) and
further sonicated using an ultrasound-130 Watt ultra-
sonic processor Sonics Vibra-Cell VCX-130 (Sonics &
Materials, Newtown, USA) (Ampl. 30 %, Pulse 2, 1 min).
Extraction was carried out by adding 660 μl FA and son-
icating again for 1 min. The extract was spun down for
20 min at 17.000 x g and 4 °C. Following determination
of total protein concentration using the DC Protein
Assay Kit, aliquoted extracts were dried down using a
SpeedVac at 45 °C.
Immunoprecipitation of Aβ and preparation of extracts for
MALDI-TOF
Immunoprecipitation was carried out with monoclonal
anti-Aβ antibodies (1:1 mixture of antibodies 6E10/4G8
(Covance) coupled to paramagnetic Dynabeads M-280
sheep-anti-mouse. In brief, 20-fold diluted brain extract
neutralized with 1 M Tris base, 0.5 M Na2HPO4 was in-
cubated with functionalized Dynabeads (8 μg antibody/
50 ml beads) on a rotator for 6 h at 4 °C. After incuba-
tion with the sample, beads were washed twice with PBS
pH 7.4 supplemented with 0.1 % BSA, and twice in
50 mM ammonium bicarbonate. After washing, elution
of precipitated peptides was performed by incubation of
the beads with 100 μl 0.5 % FA under vortexing for
15 min. The eluates were finally aliquoted and dried at
45 °C in a SpeedVac and stored at -80 °C. Immediately
before MALDI-TOF-MS analysis, the dried eluate ob-
tained from IP was dissolved in 20 μl of 20 % aceto-
nitrile, 0.1 % FA and sonicated in an ultrasonic water
bath for 10 min.
MALDI-TOF-MS analysis
Samples and standards were plated at 1 μl with an equal
amount of sinapinic acid (SA) (20 mg/ml in 1:1 (v/v)
mixture of acetonitrile/water) and left to dry at room
temperature. For calibration, we used 1 μl synthetic Aβ
peptides (pyroglutamate AβpE3-40/42 and Aβ4-40/42; dis-
solved at 0.01 mg/ml each in 10 mM NaOH). The
MALDI-TOF-MS experiments were performed on a Bru-
ker Daltonics MALDI Ultraflex II spectrometer equipped
with a pulsed N2 laser (337 nm) in a positive reflector
mode with delayed extraction (150 ns). The level of laser
power was adjusted before each experimental session to
allow for sufficient ionization and to avoid saturation of
MS detector. Spectra were acquired automatically for the
m/z range of 2000 – 6000 with each spectrum being the
sum of 10,000 single laser shots. The following Instrument
settings were chosen : Ion source I 25.0 kV, ion source II
21.7 kV, lens voltage 10.1 kV, reflector voltage I 26.3 kV,
reflector voltage II 13.8 kV, laser repetition rate 66 Hz.
Urea SDS-PAGE and Western-immunoblot
One-dimensional urea-Bicine/Bis-Tris/Tris/sulfate SDS-
PAGE (1D-Aβ-PAGE) was carried out as described pre-
viously [45]. Protein extracts were prepared from 12-
month-old WT and 5XFAD mouse brain hemispheres by
sequential extraction with Tris-buffered saline (TBS,
120 mM NaCl, 50 mM Tris, pH7.5) and 2 % sodium do-
decyl sulfate (SDS). In brief, brain hemispheres were ho-
mogenized in TBS in a weight:volume ratio of 1:10 using
a glass Teflon homogenizer. Following centrifugation for
20 min at 17000 x g, the resulting pellet was sonified in
2 % SDS and centrifuged for 20 min at 17000 x g. The
protein concentrations of the supernatants were deter-
mined with the Roti-Quant protein assay (Carl Roth).
Aβ peptide immunoprecipitation was carried out with
mAb6E10 (Covance) as previously described [18, 45].
For Western-immunoblot analysis, samples with a pro-
tein concentration of 2 mg/mL were prepared in electro-
phoresis sample buffer (final composition: 0.36 M
Bistris, 0.16 M bicine, 15 % (w/v) sucrose, 1 % (w/v)
SDS, 0,0075 % bromophenol blue). Of each sample,
10 μL (20 μg of total protein) were separated on a
10 % T / 5 % C urea Bicine/Bis-Tris/Tris-sulfate SDS-
polyacrylamide gel and blotted onto a PVDF membrane
for 45 min at 1 mA /cm2 with a discontinuous buffer
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system, essentially as described in [56]. The blot sand-
wich was assembled from the anode (+) to the cathode
(-) by stacking 1 filter paper (extra thick blot paper,
Biorad) soaked in 0.21 M Tris / 30 % methanol, 1 filter
paper soaked in 25 mM Tris / 30 % methanol, the
PVDF-membrane preequilibrated in 25 mM Tris / 30 %
methanol, the polyacrylamide gel briefly pre-incubated
in 25 mM Tris-borate, pH 9.0 / 0.025 % SDS and 2 filter
papers soaked with 25 mM Tris-borate, pH 9.0 /
0.025 % SDS. After the electrophoretic transfer, the
PVDF membranes were boiled for 3 min in PBS in a
microwave oven to facilitate the immunodetection [21].
The blots were blocked overnight at 4 °C with 2 % GE-
block in PBS-T (PBS with 0.075 % (v/v) Tween-20) and
subsequently probed with mAb1E8 for 1 h at room
temperature: After 3 x 10 min washing with PBS-T, the
biotinylated secondary anti-mouse IgG antibody
(Linaris) was applied for 45 min. After 3x washing with
PBS-T, the blot was incubated with streptavidin-coupled
horseradish peroxidase for 45 min at room temperature
[18]. Following 3 x 10 min washing with PBS-T, the
blots were developed with ECL-prime (GE-Healthcare)
for 5 min at room temperature, and the signals were re-
corded with a LiCor imager. A mixture of the synthetic
Aβ peptides (Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-40, Aβ1-42)
served as a reference for the electrophoretic mobility of
the different Aβ variants.
Results
Sporadic AD
Aβ37 and Aβ39 immunoreactivity was detected in the
majority of sporadic AD brains investigated (8 of 13
each) (Table 1; Fig. 1). Like Aβ38 and Aβ40, both pep-
tides were mainly present in the vasculature of those
cases presenting with abundant CAA. In contrast, none
of 8 NDC subjects presented Aβ37 and Aβ39 immuno-
reactivity in parenchyma or vessels. Unlike Aβ40, the
shorter peptide species Aβ37, Aβ38 and Aβ39 were
scarcely detected within amyloid plaques, although con-
siderable plaque pathology was present in all sporadic
AD, as well as some non-demented control cases, as
shown by 4G8 immunohistochemistry (Table 1). In gen-
eral, both meningeal and parenchymal vessels were
stained. However, in some cases meningeal vessels
showed a more prominent immunoreactivity compared
to parenchymal vessels (Fig. 1). In order to evaluate
whether Aβ37 and Aβ39 co-localized with Aβ40, the
major Aβ peptide species found in vascular amyloid,
double immunofluorescence analysis was carried out.
While vascular deposition of Aβ37 was found to be co-
localized with Aβ40 in most cases, Aβ39 was found to
exhibit a distinct distribution which differed from the
Aβ40 staining pattern within the majority of vessels. In
addition, Aβ40 staining was observed in many vessels
which were neither stained with antibodies against Aβ37
nor Aβ39, arguing against relevant cross-reactions of the
antibodies used in the current studies (Fig. 1). In the DS
case # 18 showing Aβ39 immunoreactivity, staining was
mainly present in large meningeal vessels together with
Aβ37, while both were absent from parenchymal vessels.
In contrast, Aβ38 was found to be abundantly present in
both meningeal and parenchymal vessels. In the cases
with AD+CAA, Aβ37, Aβ38, Aβ39 and Aβ40 were
abundant in parenchymal and meningeal vessels, while in
case #15 also faint Aβ39 immunoreactivity was detected
in extracellular deposits (Additional file 1: Figure S1).
Familial AD
The analysis of FAD cases included three cases with dif-
ferent APP mutations and a case with the PSEN1 muta-
tion ΔExon9 (Table 2). In the latter, abundant
parenchymal plaques were detected, that were stained by
Aβ40 as well as by Aβ37 and Aβ38. In contrast, Aβ39
immunoreactivity was only present within the vascula-
ture but not in extracellular deposits (Fig. 2g-i).
In one case with the KM670/671NL APP (Swedish)
mutation, a mutation located in the immediate vicinity
of the β-secretase cleavage site and which has been de-
scribed to increase total Aβ production [33], Aβ39 stain-
ing was found to be mainly limited to the vasculature,
while Aβ37 could be detected within extracellular pla-
ques as well (Fig. 2a, b).
The patient with the E693G APP (Arctic) mutation
displayed severe amyloid plaque pathology, as previously
described [23]. Of the four FAD mutation brains investi-
gated, it was the only case to show Aβ39 immunoreac-
tivity within extracellular amyloid deposits, presumably
due to the overall enhancement of aggregation caused
by this intra-Aβ-coding region mutation of APP [34]
(Fig. 2).
The investigated FAD cases further included a case of
the recently described APP mutation I716F [14, 46]. To
the best of our knowledge, it was the first time that tis
mutation was analyzed with respect to the brain depos-
ition of Aβ species with varying C-termini. While Aβ42
was the predominant species within amyloid plaques,
Aβ40 and the C-terminally truncated species Aβ37 and
Aβ38 were mainly present within the vasculature, pre-
dominantly in larger meningeal vessels (Fig. 2). In the
hippocampal region Aβ37, Aβ38 and Aβ40 contributed
to plaque pathology as well, while Aβ39 did not appear
within amyloid deposits and was only faintly detected in
some of the vessels.
Transgenic mouse models
We also investigated several established transgenic AD
mouse models for the deposition of C-terminally trun-
cated Aβ peptides by immunohistochemistry (Table 3).
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In contrast to human AD cases, all of the investigated
transgenic AD mouse models exhibited Aβ37 and Aβ39
extracellular amyloid pathology to a varying degree,
while vascular Aβ37 and Aβ39 immunoreactivity is al-
most absent. Our study suggests that plaques in AD
mouse models contain a diverse spectrum of Aβ pep-
tides of varying C-termini, including the C-terminally
truncated Aβ species Aβ37, 38 and 39 (Fig. 3). 5XFAD
and APP/PS1KI mice showed the most abundant overall
extracellular amyloid plaque pathology and also the
strongest staining for Aβ37 and Aβ39. Concordantly, C-
terminal truncated Aβ species were detected in brain
tissue lysates of 5XFAD mice using 1E8 antibody in a
western blot performed following immunoprecipitation
with 6E10 and Urea SDS-PAGE (Fig. 4a). Brain tissue
from 7-month-old heterozygous 5XFAD mice was fur-
ther analyzed by mass spectrometry. In addition to sev-
eral N-terminal truncated Aβ species, Aβ1-37, Aβ1-38
and Aβ1-39 were identified, albeit less abundant than
Aβ1-40 and Aβ1-42, which corroborates the immuno-
histochemical analyses (Fig. 4b, c). Double immunofluor-
escence of Aβ37 and Aβ39 with Aβ40 revealed major
co-localization in extracellular plaques in 7-month-old
5XFAD and 10-month-old APP/PS1KI mice (Additional
file 1: Figure S2).
Discussion
Even though research has long been centered on Aβ
peptides and reports on the accumulation of Aβ40 and
Aβ42 are numerous, the deposition of the C-terminally
truncated Aβ peptides shorter than 40 amino acids in
sporadic and familial AD patients has not been thor-
oughly investigated in post-mortem tissue. Recent stud-
ies by Moro and colleagues [32], as well as by our group
[44], reported Aβ38 to be abundantly deposited within
the vasculature of SAD cases presenting severe CAA, as
Table 1 Clinical and pathological data of sporadic AD cases and non-demented controls. Aβ staining intensity: - no staining; (+)
barely detectable staining, + weak staining, ++ moderate staining, +++ abundant staining; NP neuritic plaques
4G8 Aβ37 Aβ38 Aβ39 Aβ40
No. Age Sex Braak Diagnosis ApoE NP CAA NP CAA NP CAA NP CAA NP CAA
#1 92 M IV AD 3/3 ++ + - - - + - + + +
#2 92 F IV AD 3/3 + ++ - - - + - - + +
#3 93 M IV AD 3/3 + +++ - +++ - ++ - ++ ++ +++
#4 91 M IV AD 4/2 ++ +++ - + - + - - ++ +++
#5 84 F IV AD 4/3 ++ + - + - ++ - ++ + ++
#6 91 F IV AD 4/3 ++ ++ - ++ (+) + - + ++ +++
#7 88 F IV AD 3/3 + + - - - - - - + +
#8 92 F IV AD 4/2 ++ ++ - + (+) + - + + ++
#9 79 F IV AD 4/3 ++ +++ (+) ++ (+) +++ - ++ ++ +++
#10 84 F IV AD 3/2 ++ - - - - - - - + -
#11 91 F IV AD 4/3 ++ + - (+) - - - (+) (+) +
#12 86 M IV AD 3/3 + ++ - +++ - ++ - +++ + ++
#13 88 F IV AD 3/3 ++ + - - - - - - - +
#14 96 F V AD + CAA 4/3 ++ +++ - + - +++ - ++ ++ +++
#15 82 F V AD + CAA 3/3 ++ +++ - ++ - +++ + +++ +++ +++
#16 61 F VI DS 3/3 ++ - - - - - - - + -
#17 58 M VI DS 4/3 ++ ++ (+) + + + - - ++ ++
#18 64 F V DS 3/3 ++ ++ - ++ - ++ - ++ ++ ++
#19 91 M I NDC 3/3 - - - - - - - - - -
#20 78 F I NDC 3/3 (+) - - - - - - - - +
#21 73 M 0 NDC 3/3 - - - - - - - - - -
#22 84 M I NDC 3/3 - - - - - - - - - -
#23 88 F I NDC 3/3 + - - - - - - - - -
#24 78 M I NDC 4/3 ++ + - - - + - - + ++
#25 82 F I NDC 3/3 - - - - - - - - - -
#26 70 M 0 NDC 3/2 - - - - - - - - - -
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Table 2 Familial AD cases analyzed in the present study. Aβ staining intensity: - no staining; (+) barely detectable staining, + weak
staining, ++ moderate staining, +++ abundant staining, n.a not analyzed, NP neuritic plaques
Aβ37 Aβ38 Aβ39 Aβ40 Aβ42
Age Sex Mutation NP CAA NP CAA NP CAA NP CAA NP CAA
PS1-ΔEx9 61 m ΔExon9 ++ ++ + + - + ++ ++ +++ (+)
APP-I716F 47 m I716F ++ ++ + ++ - (+) ++ ++ +++ +
APP-Arctic 64 m E693Q ++ +++ + ++ + ++ +++ ++ +++ (+)
APP-Swe 61 f KM670/671NL + ++ - ++ - + n.a. n.a. +++ (+)
Fig. 1 Vascular immunoreactivity against C-terminal truncated Aβ peptides in SAD. While Aβ38 showed an overlapping staining profile with Aβ37
(j-l) and Aβ39 (d-f), both peptides showed only a partial co-localization with Aβ40 (a-c, g-i). Scale bar: a-c, g-l: 200 μm; d-f: 50 μm
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well as in various FAD cases with underlying APP and
PSEN1 mutations. To the best of the authors’ know-
ledge, there are currently no studies available describing
the immunohistochemical analysis of the C-terminally
truncated species Aβ37 or Aβ39 in human AD cases or
transgenic mouse models. In previous biochemical studies,
both peptides have been shown to be detectable within
human CSF and blood plasma samples [27, 55] or neuro-
blastoma cells [1]. Mass spectrometry characterization of
human brain samples failed to detect Aβ1-39 in SAD and
only faintly detected Aβ1-37 in one out of five cases inves-
tigated. In contrast, both subtypes were present in one out
of three investigated cases with KM670/671NL (Swedish)
Fig. 2 Vascular and parenchymal C-terminal truncated Aβ deposits were detected in FAD. Aβ37 and Aβ42 could be detected in parenchymal Aβ
deposits, while Aβ39 showed only vascular immunoreactivity in an APP-Swe case (a-c). Abundant Aβ37-, Aβ38- and Aβ39-immunoreactivity could
be demonstrated in meningeal vessels in an APP-Arc mutation carrier (d-f). A case with the PSEN ΔEx9 mutation showed robust Aβ37- and
Aβ40-positive extracellular deposits, while Aβ39-immunoreactivity was restricted to vascular compartments (g-i). A case with the APP I716F mutation
revealed abundant Aβ37 vascular staining, but only limited Aβ39- and Aβ42-immunoreactivity (j-l). Scale bar: a-c, g-l: 100 μm; d-f: 50 μm
Table 3 Extracellular Aβ-pathology in transgenic AD mouse
models. Aβ staining intensity: + weak staining, ++ moderate
staining, +++ abundant staining, n.a not analyzed
Transgenic model Age Aβ37 Aβ38 Aβ39 Aβ40
APP/PS1ΔEx9 9 m + ++ + +++
5XFAD 7 m +++ +++ +++ +++
PDAPP 18 m + + + ++
APP23 20 m ++ n.a. ++ +++
3xTg 18 m ++ ++ ++ +++
APP/PS1KI 10 m +++ +++ +++ +++
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mutation [41]. In another recent study, Aβ1-37 and Aβ1-
39 were identified in a small fraction of AD and cases of
pathological aging but not in non-demented control sam-
ples [31]. Prelli and colleagues reported already in 1988
that cerebrovascular Aβ, although homologous to plaque
core amyloid, consists of only 39 instead of 42 amino acid
residues [42]. This finding has been partially confirmed by
Miller et al., who detected mainly Aβ1-40 with a minor
proportion of Aβ1-39 and Aβ2-39 in an analysis of cere-
brovascular amyloid [30].
In the present study, we found the two C-terminally
truncated Aβ species Aβ37 and Aβ39 to be present in
Fig. 3 Immunohistochemical analysis of Aβ37, Aβ39 and Aβ40 in APP/PS1delEx9 (a-c), APP23 (d-f), 5XFAD (g-i), 3xTg (j-l) and APP/PS1KI mice
(m-o). All peptides were detectable within extracellular deposits to a varying extent depending on the transgenic model. Scale bar: a-i: 200 μm;
j-o: 100 μm
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Fig. 4 C-terminal heterogeneity of Aβ peptides in 5XFAD mice. Immunoprecipitation using 6E10 followed by detection with 1E8 demonstrates
the presence of C-terminal truncated Aβ species in both TBS- and SDS-soluble fractions from aged 5XFAD brain lysates (a). Mass spectra of
immunoprecipitated Aβ peptides using pan Aβ antibodies 6E10 and 4G8 (used as a mix). The dominant Aβ species in 5XFAD is Aβ1-42, followed
by Aβ1-40 (b), while the C-terminal truncated species Aβ1-37, Aβ1-38 and Aβ139 could be detected in lower abundance (c)
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vascular compartments in the majority of analyzed SAD
cases and in one NDC case. The amount of deposits cor-
responded to the variable degree of CAA in the analyzed
cases, as revealed by 4G8 staining, and was generally
correlated with the deposition of Aβ38.
The observed pattern of deposition confirms in vitro
analyses of Aβ peptides with varying C-termini that ren-
dered the C-terminally truncated species to be rather
soluble and less prone to aggregation when compared to
Aβ42 [22, 52]. Although the C-terminally truncated Aβ
species seem to have similar aggregation propensities as
Aβ40, they are considerably less abundant within paren-
chymal Aβ deposits of SAD cases. This is most likely
caused by a lower production rate of the C-terminally
truncated peptides compared to Aβ40 production. While
Aβ40 typically accounts for over 50 % of Aβ production,
C-terminally truncated variants of Aβ (Aβ1-37, Aβ 1-38
and Aβ 1-39), as well as the more toxic Aβ42 species,
have been found to account for only minor fractions of
the total Aβ production in most cells [3, 12, 38]. It has
been shown that even subtle changes in the proportion
between different Aβ species can facilitate disease progres-
sion. In this respect, the Aβ42/40 ratio may be of particu-
lar significance as Aβ40 has been found to hinder the
aggregation of Aβ42 [24, 25]. This is also underscored by
a recent report showing that Aβ1-40 plays a different role
in tau pathogenesis compared to Aβ1-42. It has been
speculated that Aβ1-40 may have a protective role in tau
pathogenesis by reducing phosphorylation at Ser262, an
epitope that renders tau to be more neurotoxic [20].
Recent findings of a vast decrease of Aβ1-37, Aβ1-38
and Aβ1-39 in the CSF of FAD cases have prompted
speculation upon a similar protective function of the C-
terminally truncated Aβ species, that was absent in FAD
due to reduced production rates [40]. On the other
hand, using double-immunofluorescence staining of
SAD cases, we found Aβ39 to exhibit a virtually opposite
deposition pattern as Aβ40, while Aβ37 was found to be
mostly co-localized with Aβ40.
In different cases of FAD we found Aβ37 and Aβ39,
which had been limited to the vasculature in SAD, to con-
tribute to NPs as well. We chose different APP mutations,
located at the N-terminal (APPSwe), the mid-portion
(APPArc) and the C-terminal part of Aβ (APPI716F), in order
to allow conclusions about the mechanisms involved that
lead to deposition of the analyzed peptides. Interestingly
Aβ39 was only detected within NPs in a case carrying the
intra-Aβ E693G mutation, a mutation that has been de-
scribed to strongly enhance aggregation propensities and
hinder proteolytic degradation of Aβ [34, 51]. Conversely
Aβ37 was detected to a varying degree in NPs of all ana-
lyzed FAD cases. This might be due to an increase in Aβ42
levels in APP mutation carriers, as multiple pathways for
stepwise successive γ-secretase cleavages, including the
release of the GVVIA pentapeptide from Aβ42, have been
proposed [29]. Presenilin mutations have been demon-
strated to change the spectrum of Aβ species produced by
γ-secretase and to increase the Aβ42/Aβ40 ratio, mainly by
lowering Aβ40 production [7].
The I716F APP mutation represents a mutation in
close proximity to the ε-cleavage site of γ-secretase
[14, 46]. The recent discovery of I716F verified earlier in
vitro experiments predicting that the mutation would
cause extraordinarily severe Aβ accumulation [26].
There is ample evidence showing that the I716F APP
mutation causes drastic elevations of Aβ42 production
in vitro, with a dramatic increase in the Aβ42/Aβ40 ratio
[19, 26]. This was interpreted as a shift in Aβ product
lines due to impaired ε-cleavage of γ-secretase. Thereby
the mutation would immensely enhance the product line
starting with Aβ48 (Aβ48, Aβ45, Aβ42, Aβ38), while
suppressing the product line starting with Aβ49 (Aβ49,
Aβ46, Aβ43, Aβ40) [49]. In good agreement with these
findings, we found Aβ42 to be the predominant species
deposited in the brain of a case carrying this mutation.
On the other hand, significant amounts of Aβ40 and
Aβ37 were detected as well, underscoring their depend-
ence in terms of production, while the relative abun-
dance of Aβ37 may also underline the significance of
recently described deviations from the major product
lines of γ-secretase [29].
The analysis of a group of widely used transgenic AD
mouse models revealed Aβ37 and Aβ39 to be widely
present to a varying extent within NPs to a degree de-
pending on the overall severity of plaque pathology in
each model. Vascular Aβ37 and Aβ39 immunoreactivity
is almost absent, which might be due to the fact that
most models in general harbor only minor Aβ vessel
pathology. Mass spectrometry analysis in 5XFAD mice
revealed that C-terminal truncated Aβ variants only rep-
resent a minor proportion. However their presence
might represent a potential read-out to measure the ef-
fect of different γ-secretase modulators in vivo.
Conclusion
Taken together, our study points out that a broad
range of C-terminally modified Aβ peptides are
present within the vasculature of SAD and FAD
patients. Some of these peptide variants were also
detected within the extracellular Aβ deposits in FAD
patients, while all analyzed transgenic mouse models
based on FAD causing mutations harbor Aβ37-,
Aβ38- and Aβ39-positive plaques to a varying degree.
The exact role of these C-terminally truncated
peptides within the vasculature and the underlying
mechanisms responsible for their heterogeneity have
to be elucidated in future studies.
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Additional file
Additional file 1: Deposition of C-terminally truncated Aβ species Aβ37
and Aβ39 in Alzheimer’s disease and transgenic mouse models. Figure S1.
Immunohistochemical detection of Aβ37, Aβ38, Aβ39 and Aβ40 in a case
with AD and CAA. While Aβ37 (a) and Aβ38 (b) immunoreactivity is
restricted to vascular compartments, Aβ39 (c) and Aβ40 (d) are detectable
within vessels, as well as parenchymal extracellular amyloid deposits. Scale
bar: a-d: 100 μm. Figure S2. Aβ37 and Aβ39 peptide species are co-
localized with Aβ40 in extracellular amyloid deposits in the cortex of 7-
month-old 5XFAD mice (a), as well as 10-month-old APP/PS1KI mice (b).
Scale bar: a: 50 μm; b: 100 μm. (PDF 700 kb)
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